Genomic sequencing of tumors has contributed to new understanding of transformation biology and has also identified key drivers of disease that represent new therapeutic targets. The genomic landscape has raised important questions and challenges related to validation of targets, operationalization of the process by which mutation identification leads to appropriate therapeutic interventions, and the impact of highly personalized approaches on clinical trial development and implementation. The 2015 ASH/EHA Joint Symposium will provide two experts’ perspectives on how far the field has advanced in using genomic data to guide leukemia therapies in both the United States and in Europe.

This symposium is co-sponsored by ASH and the European Hematology Association (EHA) and will continue to focus on issues that two societies have identified as important to hematologists from countries around the world.